Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.

Cattrini C, Castro E, Lozano R, Zanardi E, Rubagotti A, Boccardo F, Olmos D.

Cancers (Basel). 2019 Sep 12;11(9). pii: E1355. doi: 10.3390/cancers11091355. Review.

2.

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients.

Cattrini C, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, Barboro P, Boccardo F.

Cancers (Basel). 2019 Sep 13;11(9). pii: E1365. doi: 10.3390/cancers11091365.

3.

Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.

Cattrini C, Cerbone L, Rubagotti A, Zinoli L, Latocca MM, Messina C, Zanardi E, Boccardo F.

Clin Genitourin Cancer. 2019 Aug;17(4):e724-e732. doi: 10.1016/j.clgc.2019.03.010. Epub 2019 Mar 28.

PMID:
31160193
4.

Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.

Cattrini C, Rubagotti A, Nuzzo PV, Zinoli L, Salvi S, Boccardo S, Perachino M, Cerbone L, Vallome G, Latocca MM, Zanardi E, Boccardo F.

Clin Genitourin Cancer. 2018 Dec;16(6):e1257-e1265. doi: 10.1016/j.clgc.2018.07.019. Epub 2018 Jul 29.

PMID:
30170989
5.

Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.

Cavo A, Rubagotti A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A, Arboscello E, Bellodi A, Spallarossa P, Cattrini C, Messina C, Boccardo F.

Ther Adv Med Oncol. 2018 Jan 9;10:1758834017745819. doi: 10.1177/1758834017745819. eCollection 2018.

6.

Prognostic Value of Preoperative Serum Levels of Periostin (PN) in Early Breast Cancer (BCa).

Nuzzo PV, Rubagotti A, Argellati F, Di Meglio A, Zanardi E, Zinoli L, Comite P, Mussap M, Boccardo F.

Int J Mol Sci. 2015 Jul 28;16(8):17181-92. doi: 10.3390/ijms160817181.

7.

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.

Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, Tienghi A, Valerio MR, Gasparini G, Amaducci L, Faedi M, Baldini E, Rubagotti A, Maltoni R, Paradiso A, Amadori D.

Eur J Cancer. 2015 Sep;51(14):1874-81. doi: 10.1016/j.ejca.2015.07.003. Epub 2015 Jul 20.

PMID:
26206258
8.

Matrix-assisted laser desorption/ionisation (MALDI) TOF analysis identifies serum angiotensin II concentrations as a strong predictor of all-cause and breast cancer (BCa)-specific mortality following breast surgery.

Boccardo F, Rubagotti A, Nuzzo PV, Argellati F, Savarino G, Romano P, Damonte G, Rocco M, Profumo A.

Int J Cancer. 2015 Nov 15;137(10):2394-402. doi: 10.1002/ijc.29609. Epub 2015 Jun 4.

9.

Safety of antiandrogen therapy for treating prostate cancer.

Ricci F, Buzzatti G, Rubagotti A, Boccardo F.

Expert Opin Drug Saf. 2014 Nov;13(11):1483-99. doi: 10.1517/14740338.2014.966686. Epub 2014 Oct 1. Review.

PMID:
25270521
10.

Periostin: a novel prognostic and therapeutic target for genitourinary cancer?

Nuzzo PV, Buzzatti G, Ricci F, Rubagotti A, Argellati F, Zinoli L, Boccardo F.

Clin Genitourin Cancer. 2014 Oct;12(5):301-11. doi: 10.1016/j.clgc.2014.02.005. Epub 2014 Feb 21. Review.

PMID:
24656869
11.

Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.

Barboro P, Salvi S, Rubagotti A, Boccardo S, Spina B, Truini M, Carmignani G, Introini C, Ferrari N, Boccardo F, Balbi C.

Int J Oncol. 2014 May;44(5):1589-98. doi: 10.3892/ijo.2014.2345. Epub 2014 Mar 14.

PMID:
24626777
12.

Complement C3f serum levels may predict breast cancer risk in women with gross cystic disease of the breast.

Profumo A, Mangerini R, Rubagotti A, Romano P, Damonte G, Guglielmini P, Facchiano A, Ferri F, Ricci F, Rocco M, Boccardo F.

J Proteomics. 2013 Jun 24;85:44-52. doi: 10.1016/j.jprot.2013.04.029. Epub 2013 Apr 30.

PMID:
23639844
13.

Dihydrotestosterone and bicalutamide do not affect periostin expression in androgen-dependent LNCaP prostate cancer cell lines.

Argellati F, Nuzzo PV, Ricci F, Mangerini R, Rubagotti A, Boccardo F.

Anticancer Res. 2013 Mar;33(3):815-20.

PMID:
23482749
14.

Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death.

Nuzzo PV, Rubagotti A, Zinoli L, Ricci F, Salvi S, Boccardo S, Boccardo F.

BMC Cancer. 2012 Dec 28;12:625. doi: 10.1186/1471-2407-12-625.

15.

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

Ricci F, Rubagotti A, Zinoli L, Mangerini R, Nuzzo PV, Carmignani G, Simonato A, Barboro P, Balbi C, Boccardo F.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1379-84. doi: 10.1007/s00432-012-1216-0. Epub 2012 Apr 10.

PMID:
22488172
16.

Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study.

Guglielmini P, Rubagotti A, Boccardo F.

Breast Cancer Res Treat. 2012 Apr;132(2):661-8. doi: 10.1007/s10549-011-1881-8. Epub 2011 Nov 18.

PMID:
22094938
17.
18.

Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.

Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F, Balbi C.

Prostate. 2011 Sep 15;71(13):1466-79. doi: 10.1002/pros.21366. Epub 2011 Feb 14.

PMID:
21321982
19.

Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer.

Boccardo F, Amadori D, Guglielmini P, Sismondi P, Farris A, Agostara B, Gambi A, Catalano G, Faedi M, Rubagotti A.

Oncology. 2010;78(3-4):274-81. doi: 10.1159/000315735. Epub 2010 Jun 8.

PMID:
20530973
20.

Gynaecomastia: the anastrozole paradox.

Bedognetti D, Rubagotti A, Zoppoli G, Boccardo F.

J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):205-6. No abstract available.

PMID:
20432826

Supplemental Content

Loading ...
Support Center